Literature DB >> 19704130

Penetration of colistin into cerebrospinal fluid.

S L Markantonis1, N Markou, M Fousteri, N Sakellaridis, S Karatzas, I Alamanos, E Dimopoulou, G Baltopoulos.   

Abstract

Colistin penetration into the cerebrospinal fluid (CSF) was studied in five critically ill adult patients receiving colistin methanesulfonate for infections by multiresistant gram-negative bacilli. Colistin concentrations were determined in paired serum and CSF samples, with the latter taken by lumbar puncture, with the exception of one patient with an external ventriculostomy. CSF-to-serum ratios (0.051 to 0.057) for all study patients coincided at all sampling times. The low level (5%) of penetration suggests inadequate bactericidal colistin concentrations in the CSF.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19704130      PMCID: PMC2772309          DOI: 10.1128/AAC.00345-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium.

Authors:  P Fernandez-Viladrich; X Corbella; L Corral; F Tubau; A Mateu
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

2.  Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with intravenous colistin sulfomethate sodium.

Authors:  M E Jiménez-Mejías; B Becerril; F J Márquez-Rivas; C Pichardo; L Cuberos; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-12       Impact factor: 3.267

3.  Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis.

Authors:  M E Jiménez-Mejías; C Pichardo-Guerrero; F J Márquez-Rivas; D Martín-Lozano; T Prados; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2002-03-19       Impact factor: 3.267

Review 4.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Successful treatment of Acinetobacter meningitis with intrathecal polymyxin E.

Authors:  Mony Benifla; Gideon Zucker; Avi Cohen; Michael Alkan
Journal:  J Antimicrob Chemother       Date:  2004-06-09       Impact factor: 5.790

6.  Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  A S Levin; A A Barone; J Penço; M V Santos; I S Marinho; E A Arruda; E I Manrique; S F Costa
Journal:  Clin Infect Dis       Date:  1999-05       Impact factor: 9.079

Review 7.  Antimicrobial agents and the central nervous system.

Authors:  E D Everett; L J Strausbaugh
Journal:  Neurosurgery       Date:  1980-06       Impact factor: 4.654

Review 8.  Antibiotic pharmacodynamics in cerebrospinal fluid.

Authors:  I Lutsar; G H McCracken; I R Friedland
Journal:  Clin Infect Dis       Date:  1998-11       Impact factor: 9.079

9.  Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, gram-negative bacilli infections: a prospective, open-label, uncontrolled study.

Authors:  Nikolaos Markou; Sophia L Markantonis; Efthimios Dimitrakis; Dimitris Panidis; Eleni Boutzouka; Stylianos Karatzas; Petros Rafailidis; Haralampos Apostolakos; George Baltopoulos
Journal:  Clin Ther       Date:  2008-01       Impact factor: 3.393

Review 10.  Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections.

Authors:  R Nau; F Sörgel; H W Prange
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

View more
  39 in total

1.  Pharmacokinetics of colistin in cerebrospinal fluid after intraventricular administration of colistin methanesulfonate.

Authors:  Roberto Imberti; Maria Cusato; Giovanni Accetta; Valeria Marinò; Francesco Procaccio; Alfredo Del Gaudio; Giorgio A Iotti; Mario Regazzi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

2.  Serum and cerebrospinal fluid levels of colistin in pediatric patients.

Authors:  Charalampos Antachopoulos; Matti Karvanen; Elias Iosifidis; Britt Jansson; Diamantis Plachouras; Otto Cars; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 3.  Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options.

Authors:  Yohei Doi; Gerald L Murray; Anton Y Peleg
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

4.  Bacterial meningitis in older adults.

Authors:  Diedre Hofinger; Larry E Davis
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 5.  Intrathecal/intraventricular colistin in external ventricular device-related infections by multi-drug resistant Gram negative bacteria: case reports and review.

Authors:  O Bargiacchi; A Rossati; P Car; D Brustia; R Brondolo; F Rosa; P L Garavelli; F G De Rosa
Journal:  Infection       Date:  2014-04-12       Impact factor: 3.553

6.  Colistin pharmacokinetics in burn patients during continuous venovenous hemofiltration.

Authors:  Kevin S Akers; Matthew P Rowan; Krista L Niece; Ian J Stewart; Katrin Mende; Jason M Cota; Clinton K Murray; Kevin K Chung
Journal:  Antimicrob Agents Chemother       Date:  2014-10-13       Impact factor: 5.191

7.  A Systematic Review of Studies Reporting Antibiotic Pharmacokinetic Data in the Cerebrospinal Fluid of Critically Ill Patients with Uninflamed Meninges.

Authors:  Nilesh Kumta; Jason A Roberts; Jeffrey Lipman; Wai Tat Wong; Gavin M Joynt; Menino Osbert Cotta
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

8.  Task force on management and prevention of Acinetobacter baumannii infections in the ICU.

Authors:  José Garnacho-Montero; George Dimopoulos; Garyphallia Poulakou; Murat Akova; José Miguel Cisneros; Jan De Waele; Nicola Petrosillo; Harald Seifert; Jean François Timsit; Jordi Vila; Jean-Ralph Zahar; Matteo Bassetti
Journal:  Intensive Care Med       Date:  2015-10-05       Impact factor: 17.440

Review 9.  Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections.

Authors:  J Alexander Viehman; M Hong Nguyen; Yohei Doi
Journal:  Drugs       Date:  2014-08       Impact factor: 9.546

10.  Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection.

Authors:  Mairi Ziaka; Sophia L Markantonis; Marizoza Fousteri; Paris Zygoulis; Dimitris Panidis; Marios Karvouniaris; Demosthenes Makris; Epaminondas Zakynthinos
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.